Synthesis, In Vitro biological screening and molecular docking studies of novel camphor-based thiazoles

Medicinal Chemistry

Volumn 10, Issue 6, 2014, Pages 600-608

  Ła̧czkowski, Krzysztof Z ^a   Misiura, Konrad ^a   Biernasiuk, Anna ^b   Malm, Anna ^b   Siwek, Agata ^b   Plech, Tomasz ^b   Ciok Pater, Emilia ^a   Skowron, Krzysztof ^a   Gospodarek, Eugenia ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antifungal drugs; Gram positive bacteria; Molecular modelling; Terpenes; Thiazoles; Thiosemicarbazones

Indexed keywords

2 CHLORO N [4 [2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOL 4 YL] PHENYL]ACETAMIDE; 2 [1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE]HYDRAZINECARBOTHIOAMIDE; 4 (4 BROMOPHENYL) 2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOLE; 4 (4 FLUOROPHENYL) 2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOLE; 4 (4 METHOXYPHENYL) 2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOLE; 4 (4 NITROPHENYL) 2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOLE; 4 (BIPHENYL 4 YL) 2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOLE; 4 PHENYL 2 [2 (1,7,7 TRIMETHYBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOLE; 4 [2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOL 4 YL]BENZONITRILE; 4,4' [2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOL 4 YL]BIPHENYL; 6 [2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOL 4 YL]BENZO[D]OXAZOL 2(3H) ONE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CAMPHOR DERIVATIVE; CIPROFLOXACIN; FLUCONAZOLE; MICROBIAL ENZYME; N [4 [2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOL 4 YL]PHENYL] ACETAMIDE; N [4 [2 [2 (1,7,7 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YLIDENE)HYDRAZINYL]THIAZOL 4 YL]PHENYL] METHANESULFONAMIDE; PROTEIN N MYRISTOYLTRANSFERASE; SECRETED ASPARTIC PROTEINASE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CAMPHOR; FUNGAL PROTEIN; LIGAND;

ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; BACILLUS CEREUS; BACILLUS SUBTILIS; BINDING AFFINITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIGAND BINDING; MICROCOCCUS LUTEUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STRUCTURE ACTIVITY RELATION; BINDING SITE; CANDIDA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GRAM POSITIVE BACTERIUM; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIAL PROTEINS; BINDING SITES; CAMPHOR; CANDIDA; FUNGAL PROTEINS; GRAM-POSITIVE BACTERIA; LIGANDS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; THIAZOLES;

EID: 84906232604     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/15734064113096660054     Document Type: Article

References (35)

1. Feher, M.; Schmidt, J.M. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J. Chem. Inf. Comput. Sci., 2003, 43, 218-27.
2. Lombardo, F.; Shalaeva, M.Y.; Tupper, K.A.; Gao, F.; Abraham, M.H. ElogPoct: A tool for lipophilicity determination in drug discovery. J. Med. Chem., 2000, 43, 2922-2928.
3. Rheinwald, J.G.; Chakrabarty, A.M.; Gunsalus, I.C. A Transmissible plasmid controlling camphor oxidation in Pseudomonas putida. Proc. Natl. Acad. Sci. U. S. A., 1973, 70, 885-889.
4. Espinel-Ingroff, A. Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev. Iberoam. Micol., 2009, 26, 15-22.
5. Rogers, S.A.; Whitehead, D.C.; Mullikin, T.; Melander, Ch. Synthesis and bacterial biofilm inhibition studies of ethyl N-(2-phenethyl)carbamate derivatives. Org. Biomol. Chem., 2010, 8, 3857-3859.
6. Rykowski, Z.; Cieplik, J.; Paulus, K.; Pluta, J.; Gubrynowicz, O. Synthesis and biological activity of 5-Aminopyrimidineterpenes. Sci. Pharm., 2007, 75, 1-7.
7. Klimesova, V.; Koci, J.; Palat, K.; Stolarikova, J.; Dahse, H.-M.; Mollmann, U. Structure-Activity relationships of 2-benzylsulfanylbenzothiazoles: synthesis and selective antimycobacterial properties. Med. Chem., 2012, 8, 281-292.
8. Nam, N.H.; Dung, P.T.P.; Thuong, P.T. Synthesis and biological evaluation of a series of 2-(substituted-phenyl)benzothiazoles. Med. Chem., 2011, 7, 127-134.
9. Karegoudar, P.; Karthikeyan, M.S.; Prasad, D.J.; Mahalinga, M.; Holla, B.S.; Kumari, N.S. Synthesis of some novel 2,4-disubstituted thiazoles as possible antimicrobial agents. Eur. J. Med. Chem., 2008, 43, 261-267.
10. Bharti, S.K.; Nath, G.; Tilak, R.; Singh, S.K. Synthesis, antibacterial and anti-fungal activities of some novel Schiff bases containing 2,4-disubstituted thiazole ring. Eur. J. Med. Chem., 2010, 45, 651-660.
11. De Logu, A.; Saddi, M.; Cardia, M.C.; Borgna, R.; Sanna, C.; Saddi, B.; Maccioni, E. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans. J. Antimicrob. Chemother., 2005, 55, 692-698.
12. Chimenti, F.; Bizzarri, B.; Maccioni, E.; Secci, D.; Bolasco, A.; Fioravanti, R.; Chimenti, P.; Granese, A.; Carradori, S.; Rivanera, D.; Lilli, D.; Zicari, A.; Distinto, S. Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp. Bioorg. Med. Chem. Lett., 2007, 17, 4635-4640.
13. Youssef, A.M.; Malki, A.; Badr, M.H.; Elbayaa, R.Y.; Sultan, A.S. Synthesis and anticancer activity of novel benzimidazole and benzothiazole derivatives against HepG2 liver cancer cells. Med. Chem., 2012, 8, 151-162.
14. Liu, W.; Zhou, J.; Zheng, Y.; Qi, F.; Zhang, H.; Qian, H.; Wang, J.; Cheng, Y.; Gust, R. Design, synthesis and antiproliferative activity of 2-Acetamidothiazole-5-carboxamide derivatives. Med. Chem., 2012, 8, 587-594.
15. Georgopapadakou, N.H.; Walsh, T.J. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother., 1996, 40, 279-291.
16. Sheehan, D.J.; Hitchcock, Ch.A.; Sibley, C.M. Current and emerging azole antifungal agents. Clin. Microbiol. Rev., 1999, 12, 40-79.
17. czkowski, K.Z.; Misiura, K.; Biernasiuk, A.; Malm, A.; Siwek, A.; Plech, T. Synthesis, antimicrobial activities and molecular docking studies of novel 6-hydroxybenzofuran-3(2H)-one based 2,4-disubstituted 1,3-thiazoles. Lett. Drug Des. Discov., 2013, 10, 798-807.
18. Somogyi, L. Unexpected transformations of camphor (thio)semicarbazones under acetylating conditions. Liebigs Ann. Chem., 1991, 1267-1271.
19. European Committee for Antimicrobial Susceptibility Testing (EUCAST) (2003) determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth dilution. EUCAST discussion document E. Dis 5.1. Clin. Microbiol. Infect., 2003, 9, 1-7.
20. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2012.
21. Trott, O.; Olson, A. J. AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem., 2010, 31, 455-461.
22. www.pdb.org and the following citation
23. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res., 2000, 28, 235-242.
24. Podust, L.M.; von Kries, J.P.; Nasser Eddine, A.; Kim, Y.; Yermalitskaya, L.V.; Kuehne, R.; Ouellet, H.; Warrier, T.; Alteköster, M.; Lee, J.-S.; Rademann, J.; Oschkinat, H.; Kaufmann, S.H.E.; Waterman, M.R. Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography. Antimicrob. Agents Chemother., 2007, 51, 3915-3923.
25. Isupov, M.N.; Obmolova, G.; Butterworth, S.; Badet-Denisot, M.-A.; Badet, B.; Polikarpov, I.; Littlechild, J.A.; Teplyakov, A. Substrate binding is required for assembly of the active conformation of the catalytic site in Ntn amidotransferases: evidence from the 1.8 A crystal structure of the glutaminase domain of glucosamine 6-phosphate synthase. Structure, 1996, 4, 801-810.
26. Cutfield, S.M.; Dodson, E.J.; Anderson, B.F.; Moody, P.C.; Marshall, C.J.; Sullivan, P.A.; Cutfield, J.W. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure, 1995, 3, 1261-1271.
27. Sogabe, S.; Masubuchi, M.; Sakata, K.; Fukami, T.A.; Morikami, K.; Shiratori, Y.; Ebiike, H.; Kawasaki, K.; Aoki, Y.; Shimma, N.; D'Arcy, A.; Winkler, F.K.; Banner, D.W.; Ohtsuka T. Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors. Chem. Biol., 2002, 9, 1119-1128.
28. Bertrand, J.A.; Auger, G.; Fanchon, E.; Martin, L.; Blanot, D.; van Heijenoort, J.; Dideberg, O. Crystal structure of UDP-Nacetylmuramoyl-L-Alanine: D-glutamate ligase from Escherichia coli, EMBO J., 1997, 16, 3416-3425.
29. Brousse, B.N.; Moglioni, A.G.; Martins Alho, M.; Álvarez-Larena, Á.; Moltrasio, G.Y.; D'Accorsob, N.B. Behavior of thiosemicarbazones derived from some terpenones under acetylation conditions. ARKIVOC, 2002, x, 14-23.
30. Shinabarger, D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Investig. Drugs, 1999, 8, 1195-1202.
31. Pintér, G.; Bereczki, I.; Rth, E.; Sipos, A.; Varghese, R.; Udo, E.E.; Ostorházi, E.; Rozgonyi, F.; Phillips, O.A.; Herczegh, P. The effect of systematic structural modifications on the antibacterial activity of novel oxazolidinones. Med. Chem., 2011, 7, 45-55.
32. Oefner, C.; Douangamath, A.; D'Arcy, A.; Häfeli, S.; Mareque, D.; Mac Sweeney, A.; Padilla, J.; Pierau, S.; Schulz, H.; Thormann, M.; Wadman, S.; Dale, G.E. The 1.15A crystal structure of the Staphylococcus aureus methionyl-Aminopeptidase and complexes with triazole based inhibitors. J. Mol. Biol., 2003, 332, 13-21.
33. Jalaie, M.; Erickson, J.A. Homology model directed alignment selection for comparative molecular field analysis: Application to photosystem II inhibitors. J. Comput. Aid. Mol. Des., 2000, 14, 181-197.
34. McCarthy, O.K.; Schipani, A.; Musso Buendía, A.; Ruiz-Perez, L.M.; Kaiser, M.; Brun, R.; González Pacanowska, D.; Gilbert, I.H. Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPase. Bioorg. Med. Chem. Lett. 2006, 16, 3809-3812.
35. Young, D.C. Computational drug design: a guide for computational and medicinal chemists, John Wiley & Sons, 2009.